Veradermics (MANE) Stock Price, News & Analysis

Company Overview

MANE is a global manufacturer and supplier of flavors, fragrances and ingredients for the food, beverage, personal care, household and fine fragrance markets. Headquartered in France, the company develops and produces aromatic solutions that are used by consumer goods companies, food processors, perfumers and formulators seeking sensory impact, taste modulation and olfactory character for their products.

The company’s product portfolio includes savory and sweet flavor systems, beverage concentrates, natural extracts, essential oils, fragrance compounds, cosmetic ingredients and specialty functional solutions such as taste enhancers and odor masking agents. MANE also provides tailored services including formulation, sensory evaluation, application development, regulatory support and consumer insight testing to help customers translate concepts into manufacturable products and meet evolving regulatory and labeling requirements.

MANE operates a global network of research and development centers, production sites and application labs across Europe, the Americas and the Asia‑Pacific region, enabling regional customization and closer collaboration with multinational and local customers. The company emphasizes innovation, sustainability and use of natural and responsibly sourced raw materials as part of its product development and supply chain practices, positioning itself as a partner for companies seeking sensory differentiation and regulatory-compliant solutions.

Key Stats

• Today's Range: $122.88 to $130.86
• 50-Day Range: $67.66 to $129.86
• 52-Week Range: $32.00 to $131.24
• Volume: 570,016 shs
• Average Volume: 555,547 shs
• Market Capitalization: $5.43 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $114.20
• Consensus Rating: Moderate Buy

Veradermics Stock Analysis - MarketRank™

Veradermics scored higher than 15% of companies evaluated by MarketBeat, and ranked 83rd out of 95 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Veradermics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Downside Risk

Veradermics has a consensus price target of $114.20, representing about 12.1% downside from its current price of $129.86.

Amount of Analyst Coverage

Veradermics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Veradermics is -98.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Veradermics is -98.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.97% of the float of Veradermics has been sold short.

Short Interest Ratio / Days to Cover

Veradermics has a short interest ratio ("days to cover") of 5.96.

Change versus previous month

Short interest in Veradermics has recently increased by 5.47%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veradermics does not currently pay a dividend.

Dividend Growth

Veradermics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for MANE on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

2 people have added Veradermics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Veradermics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Veradermics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 7/05/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:MANE
• CIK: 1827635
• Web: N/A
• Phone: (228) 372-3376
• Fax: N/A
• Employees: 19
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Veradermics: $114.20
• High Price Target: $136.00
• Low Price Target: $75.00
• Potential Upside/Downside: -12.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 41,779,000
• Free Float: N/A
• Market Cap: $5.43 billion
• Optionable: N/A
• Beta: N/A